Amarin reported $0 in Debt for its fiscal quarter ending in March of 2025.


Debt Change Date
AbbVie USD 69.89B 2.74B Mar/2025
Alnylam Pharmaceuticals USD 1.3B 271.5M Jun/2025
Amarin USD 0 0 Mar/2025
AstraZeneca USD 32.84B 1.19B Jun/2025
DBV Technologies USD 8.29M 8.29M Jun/2025
GlaxoSmithKline GBP 17.35B 1.08B Jun/2025
Halozyme Therapeutics USD 1.51B 1.65M Jun/2025
Ionis Pharmaceuticals USD 1.42B 169.27M Jun/2025
Neurocrine Biosciences USD 439.1M 8.4M Jun/2025
Novartis USD 31.27B 12M Mar/2025